WHAT: Women who take a common class of osteoporosis drugs to prevent hip and spine fractures may actually need to limit treatment or take a break from this popular therapy, because these drugs can cause fractures in the thigh bones and tissue decay in the jaw bone. The Food and Drug Administration will review this issue Friday when the agency convenes an advisory panel to make recommendations on bisphosphonates.
Researchers at Loyola University Health System have studied bisphosphonates and found that bone density remains stable for three years in patients who take a break or drug holiday from these treatments. A Loyola physician is available to comment on this research and weigh in on the advisory panel outcome.
MEDIA: To interview a Loyola physician, please call Nora Plunkett in Loyola Media Relations, (708) 216-6268.